DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/r3r7m9/targeting_tight) has announced the addition of the "Targeting Tight Junctions in Cancer Drug Pipeline Update 2015" report to their offering.
Epithelial tight junctions (TJs) are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes.
There are today 92 companies plus partners developing 82 tight junction targeting drugs in 366 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 47 drugs.
Targeting Tight Junctions In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 101 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 100 out of the 101 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 18 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 6
- Pre-registration - 1
- Phase III - 7
- Phase II - 41
- Phase I - 36
- Preclinical - 55
- No Data - 4
- Suspended - 1
- Ceased - 47
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/r3r7m9/targeting_tight